Five-Year watch: tracking a new psoriasis Drug's Real-World impact
NCT ID NCT06104644
Summary
This study is observing how well a medication called deucravacitinib works for adults with moderate-to-severe plaque psoriasis in everyday German clinics over five years. It will follow 550 patients who have already been prescribed the drug by their doctor to see how much their skin clears and if their quality of life improves. The goal is to understand the long-term benefits and patient satisfaction with this treatment in a real-world setting, not a controlled trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dermatologische Spezial- und Schwerpunktpraxis Selters
Selters, Rhineland-Palatinate, Germany
-
Local Institution - 0001
Selters, 56242, Germany
Conditions
Explore the condition pages connected to this study.